Business Context and Reporting Period
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, specifically pain and depression. The reporting period covers the fiscal year ended December 31, 2015. The company completed its Initial Public Offering (IPO) on November 24, 2015, listing on the NASDAQ Capital Market under the symbol "AXSM."
The company's pipeline centers on two late-stage candidates:
- AXS-02: An oral, non-opioid therapy for chronic pain (Complex Regional Pain Syndrome, knee osteoarthritis, and chronic low back pain). A Phase 3 trial for CRPS was initiated in July 2015.
- AXS-05: A fixed-dose combination of dextromethorphan and bupropion for treatment-resistant depression (TRD) and agitation in Alzheimer's disease. A Phase 3 trial for TRD was initiated in March 2016.
Key Financial Metrics
The company has not generated any revenue from product sales and expects to incur losses for the foreseeable future.
| Financial Metric (in millions) | 2015 | 2014 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(10.6) | $(6.0) |
| Research & Development Expenses | $6.8 | $4.3 |
| General & Administrative Expenses | $2.4 | $1.4 |
| Cash and Cash Equivalents (Year End) | $48.0 | $2.6 |
| Accumulated Deficit | $(18.8) | $(8.2) |
| Net Loss Per Share (Basic & Diluted) | $(0.88) | $(0.66) |
Liquidity: As of December 31, 2015, the company held $48.0 million in cash, primarily derived from the IPO (net proceeds of ~$45.5 million) and convertible note issuances. Management anticipates this cash will fund operations into the third quarter of 2017.
Material Changes vs. Prior Period
- Capital Raise: The most significant change was the completion of the IPO in November 2015, raising approximately $51.0 million in gross proceeds. This transformed the company's liquidity position from $2.6 million in cash at the end of 2014 to $48.0 million at the end of 2015.
- Operating Expenses: Total operating expenses increased by 62% to $9.2 million in 2015 from $5.7 million in 2014.
- R&D: Increased by $2.5 million, driven by the initiation of the Phase 3 trial for AXS-02 in CRPS, increased manufacturing costs, and higher personnel/stock-based compensation.
- G&A: Increased by $1.0 million, primarily due to costs associated with becoming a public company (legal, compliance, accounting) and increased personnel costs.
- Debt Extinguishment: The company recorded a $2.4 million loss on the extinguishment of debt in 2015 due to amendments of convertible notes prior to the IPO. This compares to a $2.9 million loss in 2014.
- Non-Cash Items: Interest and amortization income decreased to $0.9 million in 2015 from $2.2 million in 2014, largely due to the amortization of debt premiums associated with note amendments.
Guidance, Outlook, and Risks
Outlook: The company expects to continue incurring substantial and increasing operating losses as it advances Phase 3 clinical trials for AXS-02 and AXS-05. It does not expect to generate significant revenue until regulatory approval and commercialization are achieved.
Management Commentary:
- Management believes current cash resources are sufficient to fund operations into Q3 2017.
- Future funding requirements will depend on clinical trial progress, regulatory outcomes, and the costs of establishing a commercial infrastructure.
- The company plans to initiate Phase 3 trials for AXS-02 in knee osteoarthritis (Q1 2016) and chronic low back pain (Q4 2016/Q1 2017).
Risks and Contingencies:
- Capital Requirements: The company will need additional financing to complete development and commercialization. There is no guarantee that additional funding will be available on acceptable terms.
- Clinical Trial Risk: Failure of Phase 3 trials to meet primary endpoints or safety concerns could halt development.
- Regulatory Risk: The company relies on the 505(b)(2) regulatory pathway, which involves reliance on prior FDA findings. Delays or rejections by the FDA are possible.
- Intellectual Property: The company licenses key IP from an entity owned by its CEO/Chairman, creating potential conflicts of interest.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $48.0 million cash balance to fund operations through Q3 2017, considering the high burn rate of clinical-stage biopharma.
- Phase 3 Trial Status: Monitor enrollment and interim data for the CREATE-1 study (AXS-02 in CRPS) and the STRIDE-1 study (AXS-05 in TRD).
- Regulatory Pathway: Confirm continued alignment with the FDA regarding the 505(b)(2) pathway and Special Protocol Assessments (SPA) for knee osteoarthritis.
- Related Party Transactions: Review the terms of the license agreements with Antecip Bioventures II LLC (owned by the CEO) regarding royalty obligations (1.5% to 4.5% of net sales).
- Dilution Risk: Assess the impact of future equity issuances required to fund operations beyond the current cash runway.